|

Calderasib Clinical Trials

6 actively recruiting trials across 5 locations

No change since May 2026

Also known as: MK-1084

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 4

Top Sponsors

  • Merck Sharp & Dohme LLC6

Indications

  • Cancer6
  • Lung Cancer3
  • Non Small Cell Lung Cancer3
  • Neoplasm Malignant1
  • Rectal Adenocarcinoma1

Other1 trial

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Phase 3

Birmingham, Alabama1 trial

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Central Alabama Research ( Site 0108)

Phase 3

Bakersfield, California1 trial

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

CBCC Global Research, Inc. ( Site 0123)

Phase 3

Los Angeles, California1 trial

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Los Angeles Hematology Oncology Medical Group ( Site 0084)

Phase 3

Tampa, Florida1 trial

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Moffitt Cancer Center ( Site 0261)

Phase 1

Baltimore, Maryland1 trial

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

Greater Baltimore Medical Center ( Site 1104)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.